World South Korea pharma Celltrion's COVID test gets U.S. emergency use authorisation

06:10  26 october  2020
06:10  26 october  2020 Source:   reuters.com

Tiered lockdowns are reviving the north-south divide

  Tiered lockdowns are reviving the north-south divide The North has become the epicentre of England's second wave of coronavirus, with the toughest restrictions imposed in some areas. Sky News political editor Beth Rigby has spent this week touring the towns and cities in the North where tiered lockdowns have shattered normal life for millions of people.Walk into the centre of Bradford and the impact of COVID-19 on this city in West Yorkshire is plain to see.

South Korean drugmaker Celltrion Inc <068270.KS> said on Monday it has received regulatory approval for Phase 3 clinical trials of an experimental COVID -19 treatment. The approval comes as the company plans to seek conditional approval for its antibody drug, CT-P59, for emergency use by the

SEOUL (Reuters) - South Korea ' s Celltrion Inc said on Monday its experimental treatment of COVID -19 demonstrated an up to 100-fold reduction U . S drugmaker Gilead Science Inc has reported promising early trial results for its treatment remdesivir, prompting emergency approval in the United

SEOUL (Reuters) - South Korea's Celltrion Inc <068270.KS> said on Monday it has received emergency use authorisation (EUA) from the U.S. Food & Drug Administration (FDA) for its rapid COVID-19 testing kit Sampinute, which boosted shares of the company and its affiliates.

Celltrion said Sampinute delivers coronavirus test results within 10 minutes, with a sensitivity of around 94%.

The authorisation came three months after requesting approval in late July and the product has already been launched in the United States in August, according to the company statement.

"(The company) is planning to supply Sampinute across the United States through local wholesalers as it believes the demand for rapid diagnosis kits will be high, mainly among large businesses and government agencies that are about to return to work after telecommuting," it said in a statement.

Shares of Celltrion Inc surged as much as 4.6%, while Celltrion Pharm <068760.KQ> and Celltrion Healthcare <091990.KQ> jumped 4.6% and 1.6%, respectively. Broader KOSPI <.KS11>, however, was trading down 0.1% as of 0208 GMT.

(Reporting by Joori Roh; Editing by Kim Coghill)

Clashes in Spain over virus restrictions for second night .

usr: 22
This is interesting!